SELECTIVE LUNG TISSUE ABLATION
20170258509 · 2017-09-14
Inventors
Cpc classification
A61B2018/1472
HUMAN NECESSITIES
A61B2018/044
HUMAN NECESSITIES
A61B18/00
HUMAN NECESSITIES
A61B18/1492
HUMAN NECESSITIES
A61B18/0206
HUMAN NECESSITIES
A61B2018/0212
HUMAN NECESSITIES
A61M16/0463
HUMAN NECESSITIES
A61B2018/00994
HUMAN NECESSITIES
A61B2018/00214
HUMAN NECESSITIES
A61N5/1001
HUMAN NECESSITIES
A61B2018/1861
HUMAN NECESSITIES
International classification
A61B18/00
HUMAN NECESSITIES
A61N5/10
HUMAN NECESSITIES
Abstract
Medical methods and systems are provided for effecting lung volume reduction by selectively ablating segments of lung tissue.
Claims
1. A treatment system for ablating a targeted treatment site in a lung of a patient, comprising: a shaft having a proximal end and a distal end; an energy emitting element disposed near the distal end of the shaft, wherein the energy-emitting element comprises an elongate member which will extend through the target site in the lung and an expansion element configured to enable the energy-emitting element to be expanded to conform to a shape of the airway of the treatment site; one or more electronic temperature sensors; and wherein said sensors are connected to a feedback control system configured to control the pressure or temperature between the targeted treatment site versus the neighboring lung tissue to selectively ablate lung tissue.
2. A treatment system as in claim 1, wherein the energy emitting element comprises an elongate coil shaped electrode.
3. A treatment system as in claim 1, wherein the energy emitting element comprises an elongate braided wire electrode.
4. A treatment system as in claim 1, wherein the expansion element comprises an inflatable balloon.
5. A treatment system as in claim 1, wherein the expansion element comprises a constraint which can be released to allow the expansion element to self-expand.
6. A treatment system as in claim 1, wherein the energy emitting element comprises an electrically resistive coil or a hot fluid element.
7. A method for selectively ablating a treatment region in a lung comprising: advancing a treatment apparatus through an airway toward the treatment region in the lung; exchanging energy through the treatment apparatus to heat or cool the treatment region to a level to collapse at least a portion the treatment region; and protecting adjacent regions in the lung and surrounding tissue from thermal damage by controlling pressure or temperature at the treatment region and at one or more untreated regions adjacent the treatment region.
8. A method as in claim 7, wherein the tissue is raised to a temperature in the range from 40° C. to 95° C.
9. A method as in claim 7, wherein the delivered energy comprises radiofrequency, alternating current, microwave, ultrasound, coherent light, incoherent light, radioisotopes, or a combination thereof.
10. A method as in claim 7, further comprising advancing at least one additional treatment apparatus toward the treatment site in the lung region and delivering energy to the treatment site through at least two treatment apparatuses.
11. A method as in claim 7, further comprising ventilating the patient's other lung.
12. A method as in claim 11, further comprising ventilating untreated region(s) of the lung adjacent to the treated region.
13. A method as in claim 7, further comprising controlling pressure and temperature simultaneously in the treatment site and in the one or more untreated regions adjacent the treatment site so that thermal damage to the non-targeted sites is minimized.
14. A method as in claim 7, further comprising introducing an electrically or thermally conducting fluid into the treatment site to improve energy distribution.
15. A method as in claim 14, further comprising deploying isolation barriers to inhibit the conductive fluid from migrating from the treatment site.
16. A method as in claim 7, wherein the treatment site comprises an entire lobe of the lung.
17. A method as in claim 7, further comprising monitoring the temperature within the treatment site and controlling the energy exchange to maintain a temperature within a desired range.
18. A method as in claim 7, further comprising: testing the patient to determine if the treatment site is subject to collateral ventilation; and ablating the treatment site only if the treatment site is subject to collateral ventilation.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
DETAILED DESCRIPTION OF THE INVENTION
[0025] The methods, apparatus, and systems of the present invention are used for delivering energy to diseased target sites within a patient lung for ablation and consequent isolation of the diseased segment to treat diseased lung regions resulting from emphysema, bronchitis, and other primary diseases. The treatment methods of the present invention are more rigorous than and intended as alternatives to the intrabronchial occlusion methods described previously for isolating diseased regions within a patient's lung. The methods of the present invention will be referred to generally hereinbelow as selective lung tissue ablation (SLTA).
[0026] Prior to treatment with the SLTA methods of the present invention, patients will usually be tested with a collateral ventilation (CV) test along with a segmental diagnostic test, such as described in U.S. patent application Ser. No. 11/296,951 (Attorney Docket No. 017534-002820US); and U.S. patent application Ser. No. 10/241733 (Attorney Docket No. 017534-1710US), both incorporated herein by reference for all purposes. Patients who test negative for the collateral ventilation test could probably benefit from the less traumatic endobronchial volume reduction treatment, which relies on placing occlusal stents in their target lung regions (U.S. Pat. No. 6,287,290). Patients who test positive for the CV measurements could be considered for the more invasive SLTA treatment procedure described herein. However, it should be appreciated that patients may receive the SLTA treatment based on a variety of reasons and will not necessarily undergo CV testing prior to receiving SLTA treatment.
[0027] The SLTA methods of the present invention may be used particularly for a treatment site in a lung that is supplied air through one or more collateral pathways. Such ablation may be desired to induce collapse in the lung region. In accordance with one aspect of the invention, there is disclosed a method of inducing one lung ventilation (OLV) in the emphysematous patient. This may be achieved with the use of a variety of devices. For example,
[0028] OLV could also be introduced by other methods, such as with the use of an endobronchial blocker catheter. Or, with the use of a smaller diameter endobronchial tube 20, such as illustrated in
[0029] The left side of the lung (dependent lung DL) can thus be isolated and ventilated from the right side of the lung (nondependent lung NL). By puncturing the chest wall with a needle placed percutaneously, the nondependent lung NL can be collapsed. Alternatively, the puncture could be created from inside the inside of the lung, preferably through the wall adjacent to the treatment site that will be sealed during ablation. This separates the target lung region(s) from the chest wall which is intended to minimize thermal damage which may be caused by the ablation process.
[0030] Since emphysematous or other diseased lung tissue may not collapse easily on it's own, an isolation/aspiration procedure may optionally be performed to collapse the target lung region as much as possible. If, for example, the right upper lobe is diseased, an isolation sheath 30 may be introduced over a bronchoscope (as described in U.S. Pat. No. 6,585,639 incorporated herein by reference for all purposes) to isolate the target site (lobe or segment). An additional balloon tipped isolation catheter 32 may be introduced alongside of the sheath/bronchoscope device. The balloon 34 would be positioned the way, that the feeding bronchus to the RML (right middle lobe) and RLL (right lower lobe) both would get occluded. This would close airflow to the RML and RLL, and would prevent collateral channels to backfill the target RUL, thus enhance the collapse of the target lung area. Both of these devices may be introduced, for example, either via a double lumen tube or alongside of an endobronchial tube. After inflating the balloons, an aspiration device may be connected to the working channel of the bronchoscope to facilitate the collapse of the target lung region. The target lung region is thus collapsed as much as possible, as illustrated in
[0031] Exemplary treatment apparatuses include a balloon tipped catheter, illustrated in
[0032] The treatment apparatus is positioned at the treatment site (for example one placed in segment B1 and an other placed in B2 of
[0033] Selective thermal ablation of the lung tissue is believed to cause the collagen matrix to shrink, thereby reducing the size of the target lung segment as well as closing up the collateral channels to prevent reinflation. Deleterious effects in the cells making up the tissue begin to occur at about 42.degree. C. As the temperature of the tissue increases because of the heat generated by the tissue's resistance, the tissue will undergo profound changes and eventually, as the temperature becomes high enough, that is, generally greater than 45.degree. C., the cells will die. The change of tissue resistance or impedance could be monitored and used for controlling the depth of ablation. The zone of cell death is known as a lesion and the procedure followed to create the lesion is commonly called an ablation. As the temperature increases beyond cell death temperature, complete disintegration of the cell walls and cells caused by boiling off of the tissue's water can occur. Cell death temperatures can vary somewhat with the type of tissue to which the power is being applied, but generally will begin to occur within the range of 45.degree. C. to 60.degree. C., though actual cell death of certain tissue cells may occur at a higher temperature. Optionally, polymerizing gels can be introduced to the treatment site to promote collagen cross-linking and lung volume reduction.
[0034] In addition to RF energy, other forms of energy including alternating electrical current, microwave, ultrasound, and optical, such as coherent (e.g., laser) or incoherent (e.g., light emitting diode or tungsten filament), can be used, as well as thermal energy generated from an electrically resistive coil, a hot fluid element (e.g., circulating liquids, gases, combinations of liquids and gases, etc.), radioisotopes, and the like. Thermal energy also includes the use of cold media (cryo ablation). The hot fluid element may comprise, for example, an elongated member that includes a conduit system whereby heated fluid is transported through the center of the member and then channeled outward toward the inner surface of the member. In one embodiment the heated fluid is diverted to contact the inner surface of the elongated member so that energy radiates from selected areas on the outer surface of the member corresponding to areas. Regardless of the source, energy delivered to the target lung tissue should be such that only the selected lung regions are ablated, while they are away from the chest wall to minimize thermal damage. Optionally, tissue contraction and volume reduction can be enhanced by immediately cooling a heat-ablated treatment site. For example, liquid nitrogen can be introduced following ablation to induce permanent cross-linking of the collagen.
[0035] Neighboring lobes or segments can be ventilated or just pressurized by a cooler gas or liquid to minimize thermal damage to them as well. The isolation catheter 32 of
[0036] A conductive liquid such as isotonic or hypertonic saline could also be introduced into a lobe or a segment. Air would be desirable to be removed prior to instilling the liquid. An electrode pad may be placed under the patient's chest to provide grounding. Once the liquid is in place, an electrode or plurality of electrodes would be inserted into the proximal end of the liquid pathway to communicate electrically with the instilled conductive liquid. A monopolar RF source could be activated to cause the liquid to heat up to a specific temperature.
[0037] Referring now to
[0038] Other alternative treatment is possible for closing up collateral channels: same One Lung Ventilation (OLV) technique combined with Video Assisted Thoracoscopic Surgery (VATS) and mechanically by clipping or using an RF based cut and seal device to separate the incomplete fissures between lobes. After that either EVR could be performed by placing the occlusal stents or thermal ablation would be required.
[0039] While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.